Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 343

1.

Globalization of Traditional Chinese Medicine: what are the issues for ensuring evidence-based diagnosis and therapy?

Fears R, Griffin GE, Larhammar D, Ter Meulen V, van der Meer JWM.

J Intern Med. 2019 Nov 7. doi: 10.1111/joim.12989. [Epub ahead of print] No abstract available.

PMID:
31697414
2.

Urgent action is needed to protect human health from the increasing effects of climate change.

Hobbhahn N, Fears R, Haines A, Ter Meulen V.

Lancet Planet Health. 2019 Aug;3(8):e333-e335. doi: 10.1016/S2542-5196(19)30114-7. No abstract available.

3.

Win-wins for health and climate - new report.

Fears R, Hobbhahn N, Ter Meulen V, Haines A.

Nature. 2019 Jul;571(7763):36. doi: 10.1038/d41586-019-02030-8. No abstract available.

PMID:
31267057
4.

Scientific opportunities for nutrition security.

Fears R, Ter Meulen V.

Lancet. 2019 Jun 1;393(10187):2200. doi: 10.1016/S0140-6736(19)30223-5. No abstract available.

PMID:
31162081
5.

Transforming food systems to deliver healthy, sustainable diets-the view from the world's science academies.

Fears R, Canales C, Ter Meulen V, von Braun J.

Lancet Planet Health. 2019 Apr;3(4):e163-e165. doi: 10.1016/S2542-5196(19)30038-5. Epub 2019 Feb 26. No abstract available.

6.

Assessing Security Implications of Genome Editing: Emerging Points From an International Workshop.

Fears R, Ter Meulen V.

Front Bioeng Biotechnol. 2018 Mar 28;6:34. doi: 10.3389/fbioe.2018.00034. eCollection 2018. No abstract available.

7.

Scientific opportunities for food and nutrition security.

Fears R, Ter Meulen V, von Braun J.

Lancet Planet Health. 2018 Jan;2(1):e2-e3. doi: 10.1016/S2542-5196(17)30175-4. Epub 2018 Jan 9. No abstract available.

8.

Assessing and regulating homeopathic products.

Fears R, Griffin G, Larhammar D, Ter Meulen V, van der Meer JWM.

J Intern Med. 2017 Dec;282(6):563-565. doi: 10.1111/joim.12676. Epub 2017 Sep 25. No abstract available.

PMID:
28944510
9.

How should the applications of genome editing be assessed and regulated?

Fears R, Ter Meulen V.

Elife. 2017 Apr 4;6. pii: e26295. doi: 10.7554/eLife.26295.

10.

What next for gain-of-function research in Europe?

Fears R, ter Meulen V.

Elife. 2015 Dec 30;4. pii: e13035. doi: 10.7554/eLife.13035.

11.

European Academies Advise on Gain-of-Function Studies in Influenza Virus Research.

Fears R, ter Meulen V.

J Virol. 2015 Dec 23;90(5):2162-4. doi: 10.1128/JVI.03045-15. Review.

12.

Genetic gain of function: EU report advises on contentious research.

Fears R, ter Meulen V.

Nature. 2015 Oct 29;526(7575):640. doi: 10.1038/526640d. No abstract available.

PMID:
26511570
13.

Antimicrobial innovation: combining commitment, creativity and coherence.

van der Meer JW, Fears R, Davies SC, ter Meulen V.

Nat Rev Drug Discov. 2014 Oct;13(10):709-10. doi: 10.1038/nrd4448.

PMID:
25270944
14.

What do we need to do to tackle antimicrobial resistance?

Fears R, ter Meulen V.

Lancet Glob Health. 2014 Jan;2(1):e11-2. doi: 10.1016/S2214-109X(13)70086-X. Epub 2013 Nov 18. No abstract available.

15.

Time to settle the synthetic controversy.

ter Meulen V.

Nature. 2014 May 8;509(7499):135. doi: 10.1038/509135a. No abstract available.

PMID:
24805310
16.

How should we tackle the global risks to plant health?

Fears R, Aro EM, Pais MS, ter Meulen V.

Trends Plant Sci. 2014 Apr;19(4):206-8. doi: 10.1016/j.tplants.2014.02.010.

PMID:
24698707
17.

Global networks: InterAcademy Panel to inform policy.

ter Meulen V, Hassan M, Fears R.

Nature. 2013 Jun 27;498(7455):434. doi: 10.1038/498434b. No abstract available.

PMID:
23803836
18.

The perspective from EASAC and FEAM on direct-to-consumer genetic testing for health-related purposes.

Fears R, ter Meulen V; EASAC–FEAM Working Group.

Eur J Hum Genet. 2013 Jul;21(7):703-7. doi: 10.1038/ejhg.2012.238. Epub 2012 Nov 21. Review.

19.

The changing burden of infectious disease in Europe.

Fears R, van der Meer JW, ter Meulen V.

Sci Transl Med. 2011 Oct 5;3(103):103cm30. doi: 10.1126/scitranslmed.3002556.

PMID:
21974933
20.

Health benefits of policies to mitigate climate change.

Fears R, ter Meulen V.

Lancet. 2011 Mar 19;377(9770):995-6. doi: 10.1016/S0140-6736(11)60385-1. No abstract available.

PMID:
21420552
21.

The potential of synthetic biology: a view from the European Academies Science Advisory Council.

Fears R, ter Meulen V.

Nat Rev Microbiol. 2011 Mar;9(3):222. doi: 10.1038/nrmicro2498-c1. No abstract available.

PMID:
21326277
22.

Cultivating young academies.

ter Meulen V, Stock G.

Science. 2010 Dec 10;330(6010):1455. doi: 10.1126/science.1200095. No abstract available.

23.

Increased dopaminergic neurotransmission in therapy-naïve asymptomatic HIV patients is not associated with adaptive changes at the dopaminergic synapses.

Scheller C, Arendt G, Nolting T, Antke C, Sopper S, Maschke M, Obermann M, Angerer A, Husstedt IW, Meisner F, Neuen-Jacob E, Müller HW, Carey P, Ter Meulen V, Riederer P, Koutsilieri E.

J Neural Transm (Vienna). 2010 Jun;117(6):699-705. doi: 10.1007/s00702-010-0415-6. Epub 2010 May 9.

PMID:
20454983
24.

Drug-resistant tuberculosis in the European Union: opportunities and challenges for control.

Fears R, Kaufmann S, Ter Meulen V, Zumla A; EASAC Working Group.

Tuberculosis (Edinb). 2010 May;90(3):182-7. doi: 10.1016/j.tube.2010.03.008. Epub 2010 Apr 10. Review.

PMID:
20382566
25.

Translational medicine policy issues in infectious disease.

Fears R, van der Meer JW, ter Meulen V.

Sci Transl Med. 2010 Jan 13;2(14):14cm2. doi: 10.1126/scitranslmed.3000375.

PMID:
20371464
26.

European bodies can help to tackle TB worldwide.

Fears R, Zumla A, ter Meulen V.

Nature. 2009 Aug 13;460(7257):796. doi: 10.1038/460796c. No abstract available.

PMID:
19675627
27.

Celebrating Achim Trebst's 80th birthday.

ter Meulen V, Thauer RK.

Photosynth Res. 2009 Jun;100(3):117-9. doi: 10.1007/s11120-009-9449-8. Epub 2009 Jul 4.

28.

Disruption of excitatory amino acid transporters in brains of SIV-infected rhesus macaques is associated with microglia activation.

Meisner F, Neuen-Jacob E, Sopper S, Schmidt M, Schlammes S, Scheller C, Vosswinkel D, Ter Meulen V, Riederer P, Koutsilieri E.

J Neurochem. 2008 Jan;104(1):202-9. Epub 2007 Nov 6.

29.

Biostatistical analysis of gene microarrays reveals diverse expression clusters between macaque subspecies in brain SIV infection.

Kneitz S, Meisner F, Sopper S, Kaiser F, Grünblatt E, Scheller C, Riederer P, ter Meulen V, Koutsilieri E.

J Neural Transm Suppl. 2007;(72):317-22.

PMID:
17982909
30.

Memantine upregulates BDNF and prevents dopamine deficits in SIV-infected macaques: a novel pharmacological action of memantine.

Meisner F, Scheller C, Kneitz S, Sopper S, Neuen-Jacob E, Riederer P, ter Meulen V, Koutsilieri E; German Competence Network HIV/AIDS.

Neuropsychopharmacology. 2008 Aug;33(9):2228-36. Epub 2007 Oct 31.

31.

Intrathecal viral replication and cerebral deficits in different stages of human immunodeficiency virus disease.

Arendt G, Nolting T, Frisch C, Husstedt IW, Gregor N, Koutsilieri E, Maschke M, Angerer A, Obermann M, Neuen-Jacob E, Adams O, Loeffert S, Riederer P, ter Meulen V, Sopper S; German Competence Network HIV/AIDS.

J Neurovirol. 2007 Jun;13(3):225-32.

PMID:
17613712
32.

Early impairment in dopaminergic neurotransmission in brains of SIV-infected rhesus monkeys due to microglia activation.

Scheller C, Sopper S, Jenuwein M, Neuen-Jacob E, Tatschner T, Grünblatt E, ter Meulen V, Riederer P, Koutsilieri E.

J Neurochem. 2005 Oct;95(2):377-87. Epub 2005 Aug 31.

33.

Dopamine deficits and regulation of the cAMP second messenger system in brains of simian immunodeficiency virus-infected rhesus monkeys.

Jenuwein M, Scheller C, Neuen-Jacob E, Sopper S, Tatschner T, ter Meulen V, Riederer P, Koutsilieri E.

J Neurovirol. 2004 Jun;10(3):163-70.

PMID:
15204921
34.

Caspase inhibitors as a supplement in immune activation therapies to achieve eradication of HIV in its latent reservoirs.

Scheller C, Sopper S, Koutsilieri E, Ludwig S, Ter Meulen V, Jassoy C.

Ann N Y Acad Sci. 2003 Dec;1010:209-12.

PMID:
15033722
35.

CpG oligodeoxynucleotides activate HIV replication in latently infected human T cells.

Scheller C, Ullrich A, McPherson K, Hefele B, Knöferle J, Lamla S, Olbrich AR, Stocker H, Arasteh K, ter Meulen V, Rethwilm A, Koutsilieri E, Dittmer U.

J Biol Chem. 2004 May 21;279(21):21897-902. Epub 2004 Mar 11.

36.

Modulation of simian immunodeficiency virus neuropathology by dopaminergic drugs.

Czub S, Czub M, Koutsilieri E, Sopper S, Villinger F, Müller JG, Stahl-Hennig C, Riederer P, Ter Meulen V, Gosztonyi G.

Acta Neuropathol. 2004 Mar;107(3):216-26. Epub 2004 Jan 8.

PMID:
14712399
37.

Monoamine oxidase inhibition and CNS immunodeficiency infection.

Koutsilieri E, Scheller C, ter Meulen V, Riederer P.

Neurotoxicology. 2004 Jan;25(1-2):267-70. Review.

PMID:
14697901
38.

Measles virus and immunomodulation: molecular bases and perspectives.

Schneider-Schaulies S, ter Meulen V.

Expert Rev Mol Med. 2002 May 30;4(13):1-18. doi: 10.1017/S1462399402004696. Review.

PMID:
14585153
39.

Dendritic cells and measles virus infection.

Schneider-Schaulies S, Klagge IM, ter Meulen V.

Curr Top Microbiol Immunol. 2003;276:77-101. Review.

PMID:
12797444
40.

CD46- and CD150-independent endothelial cell infection with wild-type measles viruses.

Andres O, Obojes K, Kim KS, ter Meulen V, Schneider-Schaulies J.

J Gen Virol. 2003 May;84(Pt 5):1189-97.

PMID:
12692284
41.

Expansion of human gamma/delta T cells in vitro is differentially regulated by the measles virus glycoproteins.

Bieback K, Breer C, Nanan R, ter Meulen V, Schneider-Schaulies S.

J Gen Virol. 2003 May;84(Pt 5):1179-88.

PMID:
12692283
42.

Oral immunization with recombinant Yersinia enterocolitica expressing a measles virus CD4 T cell epitope protects against measles virus-induced encephalitis.

Gundel I, Weidinger G, ter Meulen V, Heesemann J, Rüssmann H, Niewiesk S.

J Gen Virol. 2003 Apr;84(Pt 4):775-9.

PMID:
12655077
43.

Modulation of immune functions by measles virus.

Schneider-Schaulies S, ter Meulen V.

Springer Semin Immunopathol. 2002;24(2):127-48. Review.

PMID:
12503061
44.

Psychiatric complications in human immunodeficiency virus infection.

Koutsilieri E, Scheller C, Sopper S, ter Meulen V, Riederer P.

J Neurovirol. 2002 Dec;8 Suppl 2:129-33. Review.

PMID:
12491164
45.

Triggering of and interference with immune activation: interactions of measles virus with monocytes and dendritic cells.

Schneider-Schaulies S, ter Meulen V.

Viral Immunol. 2002;15(3):417-28. Review. No abstract available.

PMID:
12479392
46.

Measles virus: immunomodulation and cell tropism as pathogenicity determinants.

Schneider-Schaulies S, Schneider-Schaulies J, Niewiesk S, Ter Meulen V.

Med Microbiol Immunol. 2002 Oct;191(2):83-7. Epub 2002 Aug 17. Review.

PMID:
12410346
47.

Impact of simian immunodeficiency virus (SIV) infection on lymphocyte numbers and T-cell turnover in different organs of rhesus monkeys.

Sopper S, Nierwetberg D, Halbach A, Sauer U, Scheller C, Stahl-Hennig C, Mätz-Rensing K, Schäfer F, Schneider T, ter Meulen V, Müller JG.

Blood. 2003 Feb 15;101(4):1213-9. Epub 2002 Oct 10.

PMID:
12393472
48.

Caspase inhibitors induce a switch from apoptotic to proinflammatory signaling in CD95-stimulated T lymphocytes.

Scheller C, Sopper S, Ehrhardt C, Flory E, Chen P, Koutsilieri E, Ludwig S, ter Meulen V, Jassoy C.

Eur J Immunol. 2002 Sep;32(9):2471-80.

49.

Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling.

Bieback K, Lien E, Klagge IM, Avota E, Schneider-Schaulies J, Duprex WP, Wagner H, Kirschning CJ, Ter Meulen V, Schneider-Schaulies S.

J Virol. 2002 Sep;76(17):8729-36.

50.

Parkinsonism in HIV dementia.

Koutsilieri E, Sopper S, Scheller C, ter Meulen V, Riederer P.

J Neural Transm (Vienna). 2002 May;109(5-6):767-75. Review.

PMID:
12111466

Supplemental Content

Loading ...
Support Center